DOCSLIB.ORG

500 Mg/Ml Oral Drops, Solution Metamizole Sodium Monohydrate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
500 Mg/Ml Oral Drops, Solution Metamizole Sodium Monohydrate Package leaflet: Information for the user <invented name> 500 mg/ml oral drops, solution metamizole sodium monohydrate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What <invented name> is and what it is used for 2. What you need to know before you take <invented name> 3. How to take <invented name> 4. Possible side effects 5. How to store <invented name> 6. Contents of the pack and other information 1. What <invented name> is and what it is used for <invented name> is a medicine that contains metamizole sodium monohydrate. It belongs to a group of medicines called pyrazolones and is used for pain and fever. <invented name> is used for: acute severe pain from trauma or surgical operations colic (spasmodic stomach pain) tumour pain (cancer pain) other acute or chronic severe pain if other treatments cannot be used high fever that does not respond to other measures 2. What you need to know before you take <invented name> DO NOT take <invented name>: if you are allergic to metamizole sodium, propyphenazone, phenazone, phenylbutazone or any of the other ingredients of this medicine (listed in section 6) if you suffer from a known analgesic asthma syndrome or known analgesic intolerance of the urticaria/angiooedema type, i.e. patients who react with bronchospasm or other anaphylactoid types of reaction to salicylates, paracetamol or other non-narcotic analgesics, such as diclofenac, ibuprofen, indomethacin or naproxen if you have a bone marrow function disorder, e.g. after treatment with cytostatic medicines (medicines that treat cancer) if you have diseases of blood formation (diseases of the haematopoietic system) if you suffer from a genetic glucose-6-phosphate dehydrogenase deficiency (a hereditary defect with the risk of red blood cells breaking down) if you suffer from acute hepatic porphyria (hereditary disorder with disturbances in haemoglobin synthesis) if you are in the last three months of pregnancy Warnings and precautions Talk to your doctor or pharmacist before taking <invented name>: if you have a known intolerance to pain relievers (analgesic intolerance) if you suffer from allergy-induced bronchial asthma (attacks of shortness of breath due to an allergy) if you suffer from diseases associated with a reduced white blood cell count if your kidney function is impaired if you have known allergies, since you then have an increased tendency to a shock reaction (sudden circulatory collapse) if you suffer from any disease that is possibly caused by allergies (including events in your medical history), since you then have an increased tendency to a shock reaction This particularly affects patients with: bronchial asthma (shortness of breath caused by constriction of the smallest airways) and chronic (long- term) inflammation of the respiratory tract chronic urticaria (hives) allergy to painkillers and rheumatoid arthritis relievers (analgesic intolerance) or other medicines allergies to food, preservatives, alcoholic beverages allergy to fur or hair dye If you belong to any of these patient groups, you should take <invented name> only under a doctor’s supervision. The risk of a shock reaction is lower with metamizole sodium tablets or drops than if a medicine that contains metamizole sodium is applied with a syringe. <invented name> should be used only after careful consideration has been given to the benefit versus risk ratio and only if appropriate precautions are taken in patients with impaired renal or hepatic function. Warning <invented name> contains the pyrazolone derivative metamizole sodium, which has the rare, but life-threatening, risk of shock (sudden circulatory collapse) and of agranulocytosis (acute disorder caused by a severe reduction in the count of specific white blood cells; see section 4.). Other medicines and <invented name> Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Which other medicines influence the action of <invented name>? The pyrazolone class of active substances (to which also belongs metamizole sodium) has a known potential to cause interactions with - chlorpromazine (used to treat certain symptoms of mental illness). Combination of metamizole and chlorpromazine can cause severe hypothermia (excessively low body temperature). - medicines to prevent the blood from clotting (oral anticoagulants) - medicines for high blood pressure and certain heart diseases (captopril) - medicines to treat mental illness (lithium) - medicines to treat cancer or certain rheumatic disorders (methotrexate) - medicines to increase urine output (triamterene) - antihypertensive agents (used to treat high blood pressure) and diuretics (water tablets) as it can alter the effectiveness of these medicines Metamizole sodium may decrease the effect of acetylsalicylic acid (ASA) on the blood platelets. If you use low-dose acetylsalicylic acid for heart protection, use <invented name> with caution. On what other medicines does <invented name> have an effect? Metamizole sodium can reduce blood levels of ciclosporin (a medicine for suppressing the immune system). If taken at the same time, your dosage of ciclosporin may need to be increased. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Pregnancy Available data on the use of metamizole during the first three months of pregnancy is limited but do not indicate harmful effects to the embryo. In selected cases when no other treatment options exist, single doses of metamizole during the first and second trimester might be acceptable after consultation with your doctor or pharmacist and after the benefits and risks of metamizole use have been carefully weighed up. However, in general, the use of metamizole during the first and second trimester is not recommended. During the last three months of pregnancy you must not take <invented name> because of an increased risk of complications for the mother and child (haemorrhaging, premature closure of an important vessel, the so-called Ductus Botalli, of the unborn, which naturally closes only after birth). Breast-feeding The breakdown products of metamizole pass into breast-milk in considerable amounts and a risk to the breast-fed infant cannot be excluded. Especially the repeated use of metamizole during breast-feeding must therefore be avoided. In case of a single administration of metamizole, mothers are advised to collect and discard the breastmilk for 48 hours after the dose. Driving and using machines Taking higher amounts of <invented name> can affect the brain. In this situation you would no longer be able to react quickly and effectively to unexpected and sudden events. Do not drive a car or any other vehicle. Do not operate electrical tools or machines. Do not work unsecured. Please note that alcohol further impairs your ability to drive! However, in the recommended dosage range (see dosage table in section 3.) no special precautionary measures are necessary. <invented name> contains sodium This medicine contains 33.4 mg sodium (main component of cooking/table salt) in each ml (20 drops). This is equivalent to 1.7 % of the recommended maximum daily dietary intake of sodium for an adult. 3. How to take <invented name> Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Dosage is depended on the intensity of the pain or fever and the individual’s sensitivity of response to <invented name>. The lowest dose needed to control pain and fever should always be selected. Your doctor will tell you how to take <invented name>. The following table shows recommended single doses and maximum daily doses depending on weight or age: Body weight Single dose Daily maximum dose kg age drops mg drops mg < 9 < 12 months 1-5 25-125 4-20 100-500 9-15 1-3 years 3-10 75-250 12-40 300-1,000 16-23 4-6 years 5-15 125-375 20-60 500-1500 24-30 7-9 years 8-20 200-500 32-80 800-2,000 31-45 10-12 years 10-30 250-750 40-120 1,000-3,000 46-53 13-14 years 15-35 375-875 60-140 1,500-3,500 > 53 ≥ 15 years 20-40 500-1,000 80-160 2,000-4,000 Single doses can be given up to four times a day, depending on the maximum daily dose. A clear effect can be expected 30 to 60 minutes after oral administration. Elderly and patients in poor general health/with renal impairment The dose should be reduced in elderly people, in debilitated patients and in those with reduced renal function, as excretion of the breakdown products of metamizole may be delayed. Patients with impaired kidney or liver function As the rate of elimination is reduced in patients with impaired kidney or liver function, repeated high doses should be avoided. No dose reduction is required with short-term use only. There is no experience available with long-term use. Use in children and adolescents For the treatment of pain children and adolescents up to 14 years old can take from 8 to 16 mg of <invented name> per kilogram body weight as an individual dose (see table above). In the case of fever, a dose of 10 mg of <invented name> per kilogram body weight is generally sufficient for children: Body weight Single dose kg age drops mg < 9 < 12 months 1-3 25-75 9-15 1-3 years 4-6 100-150 16-23 4-6 years 6-9 150-225 24-30 7-9 years 10-12 250-300 31-45 10-12 years 13-18 325-450 46-53 13-14 years 18-21 450-525 Route /method of administration This medicine is for oral use.
Load more

Recommended publications
  • Metamizol Suicide - Lethal Outcome Despite Maximum Therapy
    Toxichem Krimtech 2012;79(2):71 Report from the Clinical Toxicology Committee of the Society of Toxicological and Forensic Chemistry (GTFCh) Metamizol Suicide - Lethal Outcome Despite Maximum Therapy Detlef Haase, Sabine Hübner, Silke Kunellis, Gerlinde Kotzerke, Harald König Helios Hospital Schwerin, Institute for Laboratory and Transfusion Medicine, Toxicology Department, Wismarsche Straße 393-397, D-19049 Schwerin, Germany Abstract A 70 year old female patient, suffering for years from rheumatoid arthritis and associated chronic pain was referred to the hospital by an emergency physician. Her blood pressure was no longer measurable; a hemiparesis has developed. A preliminary examination was carried out in the emergency department by a neurologist and a cerebral CT was requested. Immediately after examination, the patient suffered from hypodynamic cardiac arrest and had to be cardiopulmonary resuscitated. After stabilisation she was transferred to the Stroke Unit, where tonic-clonic convulsive seizures occurred. Toxicological general-unknown analysis of the patient's serum confirmed a suspected metamizol intoxication. Despite a maximum permissible dose of noradrenaline, she died four days after hospitalisation due to multiple organ failure. 1. Introduction 1.1. Metamizol Metamizol (novaminsulfone), closely related to phenazone and propyphenazone, is the most powerful analgesic and antipyretic of the pyrazolone derivatives and still on the market. 4-N- methyl-aminoantipyrine (MAA) is also effective, but formed through metamizol hydrolysis in the body. Patients with glucose-6-dehydrogenase deficiency should never use metamizol, be- cause a haemolytic crisis could be triggered. In addition, metamizol has a considerable poten- tial for side-effects, of which agranulocytosis is the most significant [1]. Therefore, metamizol is no more licensed in many countries.
    [Show full text]
  • Development of a SPE–UHPLC–MS/MS Methodology for the Determination of Non-Steroidal Anti-Inflammatory and Analgesic Pharmace
    Development of a SPE–UHPLC–MS/MS methodology for the determination of non-steroidal anti-inflammatory and analgesic pharmaceuticals in seawater Paula Paíga, Aleksandar Lolic´, Floris Hellebuyck, Lúcia H.M.L.M. Santos, Manuela Correia, Cristina Delerue-Matos a b s t r a c t An analytical methodology for the simultaneous determination of seven pharmaceuticals and two metabolites belonging to the non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics therapeutic groups was developed based on off-line solid-phase extraction and ultra-high performance liquid chro- matography coupled to tandem mass spectrometry (SPE–UHPLC–MS/MS). Extraction conditions were optimized taking into account parameters like sorbent material, sample volume and sample pH. Method detection limits (MDLs) ranging from 0.02 to 8.18 ng/L were obtained. This methodology was successfully applied to the determination of the selected pharmaceuticals in seawater samples of Atlantic Ocean in the Northern Portuguese coast. All the pharmaceuticals have been detected in the seawater samples, with pharmaceuticals like ibuprofen, acetaminophen, ketoprofen and the metabolite hydroxyibuprofen being the most frequently detected at concentrations that can reach some hundreds of ng/L. Keywords: Non-steroidal anti-inflammatory drugs Analgesics UHPLC–MS/MS SPE Seawater 1. Introduction Pharmaceuticals have been recognized as important emerging killifish [11]. Notwithstanding that regulatory guidance to assess environmental contaminants [1], being their occurrence reported the presence of pharmaceuticals in the aquatic environment is giv- in different environmental compartments, including surface waters ing the first steps with the Directive 2013/39/EU [12], amending [2], wastewaters [3], groundwater [4], soils [5] and, even drinking the Water Framework Directive (2000/60/EC) and the directive water [6], at trace levels (nanograms to few micrograms per liter).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Screening of 300 Drugs in Blood Utilizing Second Generation
    Forensic Screening of 300 Drugs in Blood Utilizing Exactive Plus High-Resolution Accurate Mass Spectrometer and ExactFinder Software Kristine Van Natta, Marta Kozak, Xiang He Forensic Toxicology use Only Drugs analyzed Compound Compound Compound Atazanavir Efavirenz Pyrilamine Chlorpropamide Haloperidol Tolbutamide 1-(3-Chlorophenyl)piperazine Des(2-hydroxyethyl)opipramol Pentazocine Atenolol EMDP Quinidine Chlorprothixene Hydrocodone Tramadol 10-hydroxycarbazepine Desalkylflurazepam Perimetazine Atropine Ephedrine Quinine Cilazapril Hydromorphone Trazodone 5-(p-Methylphenyl)-5-phenylhydantoin Desipramine Phenacetin Benperidol Escitalopram Quinupramine Cinchonine Hydroquinine Triazolam 6-Acetylcodeine Desmethylcitalopram Phenazone Benzoylecgonine Esmolol Ranitidine Cinnarizine Hydroxychloroquine Trifluoperazine Bepridil Estazolam Reserpine 6-Monoacetylmorphine Desmethylcitalopram Phencyclidine Cisapride HydroxyItraconazole Trifluperidol Betaxolol Ethyl Loflazepate Risperidone 7(2,3dihydroxypropyl)Theophylline Desmethylclozapine Phenylbutazone Clenbuterol Hydroxyzine Triflupromazine Bezafibrate Ethylamphetamine Ritonavir 7-Aminoclonazepam Desmethyldoxepin Pholcodine Clobazam Ibogaine Trihexyphenidyl Biperiden Etifoxine Ropivacaine 7-Aminoflunitrazepam Desmethylmirtazapine Pimozide Clofibrate Imatinib Trimeprazine Bisoprolol Etodolac Rufinamide 9-hydroxy-risperidone Desmethylnefopam Pindolol Clomethiazole Imipramine Trimetazidine Bromazepam Felbamate Secobarbital Clomipramine Indalpine Trimethoprim Acepromazine Desmethyltramadol Pipamperone
    [Show full text]
  • Different Techniques for Analysis of Aspirin, Caffeine, Diclofenac Sodium and Paracetamol: Review Article
    ISSN 2692-4374 Pharmaceutical Sciences | Review Article Different techniques for Analysis of Aspirin, Caffeine, Diclofenac Sodium and Paracetamol: Review Article Mahmoud M. Sebaiy1*, Sobhy M. El-Adl1, and Amr A. Mattar1&2 1 Medicinal Chemistry Department, Faculty of Pharmacy, Zagazig University, Zagazig, 44519, Egypt. 2 Pharmaceutical Medicinal Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt. *Аuthоrcоrrеspоndеncе: Е-mаil: mmsеbаiу@zu.еdu.еg; sеbаiуm@gmаil.cоm.Tеl: 01062780060. Fаx: 0552303266 Submitted: 27 April 2020 Approved: 11 May 2020 Published: 14 May 2020 How to cite this article: Sebaiy MM, El-Adl SM, Mattar AA. Different techniques for Analysis of Aspirin, Caffeine, Diclofenac Sodium and Paracetamol: Review Article. G Med Sci. 2020; 1(1): 013-031. https://www.doi.org/10.46766/thegms.pharma.20042701 Copyright: © 2020 Mahmoud MS. This is an open access article distributed under the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTracT Early treatment of pain is of a great importance as unrelieved pain can have profound psychological effects on the patient, and acute pain that is poorly managed initially can degenerate into chronic pain, which may prove to be much more difficult to treat. It is important to assess and treat the article,mental weand will emotional shed the aspects light on of different the pain waysas well of assome its physicalanalgesic aspects. drugs monitoring Although drug and therapyanalysis isusing a mainstay different of techniques pain treatment, in addition physical to methodsthe most such as physiotherapy (including massage and the application of heat and cold), surgery, and drug monitoring are also very valuable.
    [Show full text]
  • Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
    Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%).
    [Show full text]
  • Australian Statistics on Medicines 1999–2000
    Commonwealth Department of Health and Ageing Australian Statistics on Medicines 1999–2000 © Commonwealth of Australia 2003 ISBN 0 642 82184 4 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth available from AusInfo. Requests and inquiries concerning reproduction and rights should be addressed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra ACT 2601. Publications Approval Number: 3183 (PA7270) FOREWORD Comprehensive and valid statistics on use of medicines by Australians in the public domain should be accessible to all interested parties. From the first edition in 1992 until 1999 the Drug Utilisation SubCommittee (DUSC) produced the Australian Statistics on Medicines (ASM) for each calendar year to 1998. It is pleasing indeed to be able to present these again this year, with the inclusion of estimates for the years since the last edition. A continuous data set representing estimates of the aggregate community use (non public hospital) of prescription medicines in Australia is a key tool for the Australian Medicines Policy. The ASM presents dispensing data on most drugs marketed in Australia and is the only current source of data in Australia to cover all prescription medicines dispensed in the community. Drug utilisation data can assist the targeting and evaluation of quality use of medicines initiatives, and the evaluation of changes to the availability of medicines. It is also needed for pharmacosurveillance by regulatory and financing authorities and by the Pharmaceutical Industry. Publication of the Australian data also facilitates international comparisons of drug utilisation profiles and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes.
    [Show full text]
  • Improvement of GI Tolerance of Nsaids Using Oral Prodrug Approach
    Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2010, 2(2): 300-309 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Improvement of GI tolerance of NSAIDs using oral prodrug approach Dinesh T. Makhija and Rakesh R. Somani* Bharati Vidyapeeth’s College of Pharmacy, Belapur, Navi Mumbai, Maharashtra, India ______________________________________________________________________________ Abstract Non-steroidal anti-inflammatory drugs (NSAIDs) have been widely used for the management of inflammation, pain and nociception. Gastric intolerance caused by most of the NSAIDs used today restricts their use. Several approaches have been proposed to modify the parent NSAIDs molecule in order to reduce their gastric toxicity. Oral prodrug approach is one of such approaches. This review focuses on the various prodrug approaches used to improve the GI tolerance of NSAIDs. Keywords: Gastric intolerance, NSAIDs, Prodrugs. ______________________________________________________________________________ INTRODUCTION Non-steroidal anti-inflammatory drugs (NSAIDs) are most widely prescribed drugs for the treatment of various inflammatory disorders including rheumatoid arthritis. However, gastrointestinal, renal and cardiovascular toxicity associated with common NSAIDs limits their usefulness [1-3]. All NSAIDs are believed to inhibit the biosynthesis of prostaglandins by inhibiting the group of enzymes called cyclooxygenases (COX) [3]. In early 1990’s, two isoforms of COX were discovered, a constitutive COX-I and inducible COX-II. The COX-I enzyme is located in normal tissues and is cytoprotective, physiologically important for GI and renal functions. On other hand COX-II is pathological, found primarily in inflamed tissues [4-7]. Thus, non-selective COX inhibitors cause inhibition of both the isoforms, producing GI and renal side effects due to inhibition of COX-I.
    [Show full text]
  • Phenazone and Caffeine Citrate Intact Tympanic Membrane And, Therefore, on the Pain Which Is Reactions Or Spectrometry
    116 Analgesics Anti-inflammatory Drugs and Antipyretics Prolonged use of large doses of analgesic mixtures containing Hypersensitivity. Immediate allergic reactions to phenazone phenacetin has been associated with the development of renal have been reported.1,2 In one patient leucopenia was detected 8 1 papillary necrosis (see Effects on the Kidneys, p.98) and transi- weeks later. H2N N NH2 tional-cell carcinoma of the renal pelvis. 1. Kadar D, Kalow W. Acute and latent leukopenic reaction to anti- pyrine. Clin Pharmacol Ther 1980; 28: 820–22. Porphyria. Phenacetin is considered to be unsafe in patients 2. McCrea JB, et al. Allergic reaction to antipyrine, a marker of with porphyria because it has been shown to be porphyrinogenic hepatic enzyme activity. DICP Ann Pharmacother 1989; 23: N N in animals. 38–40. Uses and Administration Porphyria. Phenazone is considered to be unsafe in patients Phenacetin, a para-aminophenol derivative, has analgesic and with porphyria because it has been shown to be porphyrinogenic antipyretic properties. It was usually given with aspirin, caffeine, in animals. or codeine but is now little used because of adverse haematolog- (phenazopyridine) ical effects and nephrotoxicity. Interactions Phenazone affects the metabolism of some other drugs and its Preparations own metabolism is affected by other drugs that increase or re- Pharmacopoeias. In Pol. and US. USP 31 (Phenazopyridine Hydrochloride). A light or dark red to (details are given in Part 3) duce the activity of liver enzymes. Proprietary Preparations dark violet crystalline powder. Is odourless or with a slight odour. Multi-ingredient: Cz.: Dinyl†; Mironal†; Hung.: Antineuralgica; Dolor.
    [Show full text]
  • CLINICAL REVIEW(S) Clinical Review Laura Jawidzik, MD NDA 211765 Ubrogepant/UBRELVY
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211765Orig1s000 CLINICAL REVIEW(S) Clinical Review Laura Jawidzik, MD NDA 211765 Ubrogepant/UBRELVY CLINICAL REVIEW Application Type NDA Application Number(s) 211765 Priority or Standard Standard Submit Date(s) 12/26/2018 Received Date(s) 12/26/2018 PDUFA Goal Date 12/26/2019 Division/Office Division of Neurology Products/Office of New Drugs Reviewer Name(s) Laura Jawidzik, MD Review Completion Date 12/19/2019 Established/Proper Name Ubrogepant (Proposed) Trade Name Ubrelvy Applicant Allergan Sales, LLC Dosage Form(s) Tablet Applicant Proposed Dosing 50 mg or 100 mg orally; a second dose may be administered at Regimen(s) least 2 hours after the initial dose; maximum 200 mg daily Applicant Proposed Acute treatment of migraine with or without aura Indication(s)/Population(s) Recommendation on Approval of 25 mg, 50 mg, and 100 mg Regulatory Action Recommended Treatment of acute migraine with or without aura in adults Indication(s)/Population(s) (if applicable) 1 Reference ID: 4533406 Clinical Review Laura Jawidzik, MD NDA 211765 Ubrogepant/UBRELVY Table of Contents Glossary ........................................................................................................................................10 1. Executive Summary ...............................................................................................................13 1.1. Product Introduction......................................................................................................13 1.2. Conclusions
    [Show full text]
  • Use of Analgesics in the General Population
    Faculty of Health Sciences Department of Community Medicine Use of analgesics in the general population Trends, persistence, high-risk use and associations with pain sensitivity — Per-Jostein Samuelsen A dissertation for the degree of Philosophiae Doctor – May 2016 Use of analgesics in the general population: Trends, persistence, high-risk use and associations with pain sensitivity Per-Jostein Samuelsen Department of Community Medicine UiT – The Arctic University of Tromsø and Regional Medicines Information and Pharmacovigilance Center (RELIS) University Hospital of North Norway Tromsø, Norway 2016 Front page photo (slightly cropped): “Spring is in the air” by Randi Hausken (https://www.flickr.com/photos/46406832@N00/3455539162/) Creative Commons BY-SA 2.0 (https://creativecommons.org/licenses/by-sa/2.0/) The photo shows the blooming of a willow tree (Norwegian: selje). CONTENTS Summary .................................................................................................................................................. i Acknowledgements ................................................................................................................................. ii Abbreviations ......................................................................................................................................... iii List of papers .......................................................................................................................................... iv 1 Background ....................................................................................................................................
    [Show full text]
  • And Bcl-2 in Duchenne Muscular Dystrophy (Dmd) Patients
    CORRELATION AND ROLE OF NITRIC OXIDE (NO) AND BCL-2 IN DUCHENNE MUSCULAR DYSTROPHY (DMD) PATIENTS Thesis Submitted to Faculty of Science, Ain Shams University In Partial Fulfillment of Master degree of Science BY Fatma Sayed Mohamed Moawed B.Sc. Biochemistry Under Supervision Of Prof. Dr. Fahmy Tawfik Ali Prof. Dr. Nadia Y.S. Morcos Professor of Biochemistry Professor of Biochemistry Faculty of Science Faculty of Science Ain Shams University Ain Shams University Prof. Dr. Soheir Saad Korraa Professor of Medical Enviromental science National Center for Radiation Research and Technology Atomic Energy Authority 2009 ﻋﻼﻗﺔ ﻭﺩﻭﺭ ﺍﻜﺴﻴﺩ ﺍﻟﻨﻴﺘﺭﻴﻙ ﻭﺒﻰ ﺴﻰ ﺍل-2 ﻓﻰ ﻤﺭﻀﻰ ﺍﻟﺤﺜل ﺍﻟﻌﻀﻠﻰ (ﺩﻭﺸﺎﻥ) رﺳﺎﻟﺔ ﻣﻘﺪﻣــﺔ ﻣﻦ ﻓﺎﻃﻤﻪ ﺳﻴﺪ ﻣﺤﻤﺪ ﻣﻌﻮض آﺠﺰء ﻣﺘﻤﻢ ﻟﻠﺤﺼﻮل ﻋﻠﻰ درﺟﺔ اﻟﻤﺎﺟﺴﺘﻴﺮ ﻓﻰ اﻟﻜﻴﻤﻴﺎء اﻟﺤﻴﻮﻳﺔ ﺗﺤـــﺖ ﺇﺷﺮﺍﻑ .. .. اﺳﺘﺎذ اﻟﻜﻴﻤﻴﺎء اﻟﺤﻴﻮﻳﺔ اﺳﺘﺎذ اﻟﻜﻴﻤﻴﺎء اﻟﺤﻴﻮﻳﺔ ﻗﺴﻢ اﻟﻜﻴﻤﻴﺎء اﻟﺤﻴﻮﻳﺔ ﻗﺴﻢ اﻟﻜﻴﻤﻴﺎء اﻟﺤﻴﻮﻳﺔ آﻠﻴﺔ اﻟﻌﻠﻮم – ﺟﺎﻣﻌﺔ ﻋﻴﻦ ﺷﻤﺲ آﻠﻴﺔ اﻟﻌﻠﻮم – ﺟﺎﻣﻌﺔ ﻋﻴﻦ ﺷﻤﺲ ..א أﺳﺘﺎذ اﻟﻌﻠﻮم اﻟﺒﻴﺌﻴﻪ اﻟﻄﺒﻴﻪ اﻟﻤﺮآﺰ اﻟﻘﻮﻣﻲ ﻟﺒﺤﻮث وﺗﻜﻨﻮﻟﻮﺟﻴﺎ اﻹﺷﻌﺎع هﻴﺌﺔ اﻟﻄﺎﻗﺔ اﻟﺬرﻳﺔ ﻛﻠﻴﺔ ﺍﻟﻌﻠﻮﻡ - ﺟﺎﻣﻌﺔ ﻋﻴﻦ ﺷﻤﺲ 2009 Acknowledgement i Thanks to Allah first and foremost. I feel always indebted to Allah the kindest and the most beneficent and merciful. My great thanks and gratitude extend to include Professor Dr. Fahmy Tawfik Ali, Professor of Biochemistry, Former Head of Biochemistry Department, Faculty of Science, Ain Shams University for his continuous encouragement, valuable advice and criticism. Without his generous and valuable assistance, this work would lose its value. It is an honor working under his supervision. My deep thanks and gratitude to Professor Dr.Nadia Y. S. Morcos, Professor of Biochemistry, Biochemistry Department, Faculty of Science, Ain Shams University for her continuous encouragement, generous supervision, valuable advice, and great support and without her great efforts this work wouldn't complete.
    [Show full text]